The influence of serum HER-2 levels and HER-2 codon 655 polymorphism on breast cancer outcome

Neoplasma

Volumn 55, Issue 2, 2008, Pages 113-121

  Papadopoulou, E ^a   Tripsianis, G ^a   Anagnostopoulos, K ^a   Tentes, I ^a   Kakolyris, S ^a   Galazios, G ^a   Sivridis, E ^a   Simopoulos, K ^a   Kortsaris, A ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Breast cancer; HER 2; Polymorphism; Serum; Survival

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR MARKER; ERBB2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BREAST CANCER; BREAST DEVELOPMENT; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE COURSE; DISEASE PREDISPOSITION; FEMALE; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; GENOTYPE; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; ONCOGENE NEU; PROGNOSIS; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; BLOOD; BREAST TUMOR; CODON; GENETICS; MIDDLE AGED; MORTALITY;

ADULT; AGED; BREAST NEOPLASMS; CODON; FEMALE; HUMANS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 48549098604     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. WEINBERG RA. How cancer arises. Sci Am 1996; 275: 62-70.
2. MARMOR MD, SKARIA KB, YARDEN Y. Signal transduction and oncogenesis by ErbB/HER recaptors. Int J Radiat Oncol Biol Phys 2004; 58: 903-913.
3. COUSSENS L, YANG-FENG TL, LIAO Y-C et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230 : 1132-1139
4. AKIYAMA T, SUDO C, OGAWARA H et al. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986; 232: 1644-1646 (Pubitemid 16095607)
5. BARGMANN CI, HUNG MC, WEINBERG RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 1986; 319: 226-230 (Pubitemid 16128785)
6. SCHLESSINGER J. Cell signaling by receptor tyrosine kinases. Cell 2000; 103: 211-225.
7. VAN DE VIJVER MJ and NUSSE R. The molecular biology of breast cancer. Biochim Biophys Acta 1991; 1072: 33-50.
8. MARIANI-COSTANTINI R, MERIO G and FRATI L. Genomic alterations in human breast cancer: a review. Tumori, 1989; 75: 311-320. (Pubitemid 19260344)
9. TZAHAR E and YARDEN Y. The erB-2/HER2 oncogenic receptor of adenocarcinomas: From orphanhood to multiple stromal ligands. Biochim Biophys Acta 1998; 1377: M25-37.
10. SLAMON DJ, CLARK GM, WONG SG et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182
11. SLAMON D, GODOLPHIN W, JONES LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712. (Pubitemid 19147683)
12. SLAMON DJ, LEYLAND-JONES B, SHAK S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344: 783-792
13. TUBBS R, SKACER M, PETTAY J et al. Interobserver interpretative reproducibility of GOLDFISH, a first generation gold-facilitated autometallographic bright field in situ hybridization assay for HER-2/neu amplification in invasive mammary carcinoma. Am J Surj Pathol 2002; 26: 908-913
14. PAULETTI G, GODOLPHIN W, PRESS MF et al. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hydridization. Oncogene 1996; 13: 63-72.
15. IMOTO S, KITOH T and HASEBE T. Serum c-erb B2 levels in monitoring of operable breast cancer patients. Jpn J Clin Oncol 1999; 29: 336-339.
16. IMOTO S, WADA N, HASEBE T et al. Serum c-erbB-2 protein is a useful marker for monitoring tumor recurrence of the breast. Int J Cancer 2006; 120: 357-361.
17. KONG S-Y, KANG JH, KWON Y et al. Serum HER-2 concentration in patients with primary breast cancer. J Clin Pathol 2006; 59: 373-376.
18. PAPEWALLIS J., NIKITIN A. AND RAJEWSKY M. G to A polymorphism at amino acid codon 655 of the human erbB-2/HER-2 gene. Nucleic Acids Res. 1991; 19: 5452.
19. TAKANO K, OGASAHARA K et al. Contribution of hydrophobic residues to the stability of human lysozyme: calorimetric studies and X-ray structural analysis of the five isoleucine to valine mutants. J. Mol. Biol. 1995; 254: 62-76.
20. XIE D, SHU X, DENG Z et al. Population-based, case-control study of HER-2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 2000; 92: 412-417. (Pubitemid 30154823)
21. ZUBOR P, VOJVODOVA A et al. HER-2 [Ile655Val] polymorphism in association with breast cancer risk: a population-based case-control study in Slovakia. Neoplasma 2006; 3(1): 49-55. (Pubitemid 43206939)
22. PINTO D, VASCONCELOS A, COSTA A et al. HER2 polymorphism and breast cancer risk in Portugal. European J. Cancer Prevention 2004; 13: 177-181. (Pubitemid 38780673)
23. BENUSIGLIO P, LESUEUR F, LUCCARINI C et al. Common ERBB2 polymorphisms and risk of breast cancer in a white British population: a case-control study. Breast Cancer Res 2005; 7: 204-209.
24. AKISIK E and DALAY N. Estrogen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk. Exp Mol Pathol 2004; 76(3): 260-263.
25. AMEYAW M, TAYEB M, THORNTON N et al. Ethnic variation in the HER-2 codon 655 genetic polymorphism previously associated with breast cancer. J Hum Genet 2002; 47(4): 172-175.
26. PAPADOPOULOU E, SIMOPOULOS K, TRIPSIANIS G et al. Allelic imbalance of HER-2 codon 655 polymorphism among different religious/ethnic populations of northern Greece and its association with the development and the malignant phenotype of breast cancer. Neoplasma, 2007; 54(5): 367-381
27. BLOOM HJG and RICHARDSON WW. Histological grading and prognosis in breast cancer. Br J Cancer 1957; 11: 359-377.
28. th Ed. Berlin: Springer-Verlag, 1992.
29. YARDEN Y AND SLIWKOWSKI MX. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2001; 2: 127-137.
30. YASASEVER V, KARALOGLU D, YAZICI H et al. Serum neu oncoprotein levels as a tumor marker in breast cancer. J Tumor Marker Oncol 1992; 7: 33-41.
31. LEITZEL K, TERAMOTO Y, SAMPSON e et al. Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. J Clin Oncol 1992; 10: 1436-1443.
32. PAULETTI G, DANDEKAR S, RONG H et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000; 18: 3651-3664 (Pubitemid 30816223)
33. RAMPAUL RS, PINDER SE, GULLICK WJ et al. HER-2 in breast cancer-methods of detection, clinical significance and future prospects for treatment. Crit Rev Oncol Hematol 2002; 43: 231-244
34. MOLINA R, JO J, FILELLA X et al. c-erbB-2 oncoprotein, CEA and CA 15.3 in patients with breast cancer: prognostic value. Breast Cancer Res Treat 1998; 51(2): 109-119.
35. SUGANO K, USHIAMA M, FUKUTOMI T et al. Combined measurmant of the c-erbB-2 protein in breast carcinoma tissues and sera is useful as a sencitive tumor marker for monitoring tumor relapse. Int J Cancer 2000; 89: 329-336.
36. WU JT. C-erbB2 oncoprotein and its soluble ectodomain: a new potential tumor marker for prognosis early detection and monitoring patients undergoing Herceptin treatment. Clin Chim Acta 2002; 322: 11-19.
37. THRIVENI K, VIJAYALAKSHMI DESHMANE, BAPSY PP et al. Clinical utility of serum human epidermal receptor-2/neu detection in breast cancer patients. Indian J Med Res 2007; 125: 137-142.
38. SAGHATCHIAN M, GUEPRATTE S, HASENE K et al.Serum HER-2 extracellular domain: relationship with clinicobiological presentation and prognostic value before and after primary treatment in 701 breast cancer patients. Int J Biol Markers 2004; 19(1): 14-22.
39. YUAN P, XU BH and CHU DT. Correlation between serum HER-2 oncoprotein and patients with breast cancer. Chin Med Sci J. 2004; 19(3): 212-215 (Pubitemid 39362512)
40. MOLINA MA, CODONY-SERVAT J, ALBANELL J et al. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001; 61: 4744-4749.
41. ROSS JS, FLETCHER JA, BLOOM KJ et al. Targeted therapy in breast cancer: the HER-2/neu, gene and protein. Mol Cell Proteomics 2004; 3(4): 379-398 (Pubitemid 38702091)
42. MILLIKAN R, EATON A, WORLEY K et al. HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites. Breast Cancer Research and Treatment 2003; 79: 355-364.
43. KAMALI-SARVESTANI E, TALEI A and MERAT A. Ile to Val polymorphism at codon 655 of HER-2 gene and breast cancer risk in Iranian women. Cancer Letters 2004; 215: 83-87.
44. ZHENG W, KATAOKA N, XIE D, YOUNG SR. Re: Population-based, case-control study of HER-2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 2001; 93:558-559.
45. HAN W, KANG D, LEE JE et al. A haplotype analysis of HER-2 gene polymorphisms: association with breast cancer risk, Her-2 protein expression in the tumor, and disease recurrence in Korea. Clin Cancer Res 2005; 11(13):4775-4782.
46. FLEISHMAN SJ, SCHLESSINGER J and BEN-TAL N. A putative molecular-activation switch in the transmembrane domain of erbB-2. Proc Natl Acad Sci 2002; 99(25): 15937-15940
47. KANDL H, SEYMOUR L, BEZWODA WR. Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer. Br J Cancer 1994; 70: 739-742.
48. WILLSHER PC, BEAVER J, PINDER S et al. Prognostic significance of serum c-erbB-2 protein in breast cancer patients. Breast Cancer Res Treat 1996; 40: 251-255 (Pubitemid 26336120)
49. MOLINA R, JO J, FILELLA X et al. C-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer. Utility in prognosis. Anticancer Res 1996;16: 2295-2300.
50. MOLINA R, FILELLA X, JO J et al. Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA15.3) in patients with locoregional breast. Anticancer Res 2003; 23: 1043-1050.
51. PINTO D, PEREIRA D, PORTELA C et al. The influence of HER2 genotypes as molecular markers in ovarian cancer outcome. Biochem Biophys Res Commun 2005; 335: 1173-1178. (Pubitemid 41215541)